Recent approaches to the development of antigen-specific immunotherapies for myasthenia gravis

Autoimmunity

Volumn 43, Issue 5-6, 2010, Pages 436-445

  Lagoumintzis, George ^a,b   Zisimopoulou, Paraskevi ^a   Kordas, Gregory ^b   Lazaridis, Konstantinos ^a   Poulas, Konstantinos ^b   Tzartos, Socrates J ^a,b  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Acetylcholine receptor; autoantibodies; extracellular domains; monoclonal antibodies; myasthenia gravis; therapy

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; EXTRACELLULAR DOMAIN NICOTINIC RECEPTOR; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN G4 637; MAIN IMMUNOGENIC REGION MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 195; MYCOPHENOLIC ACID; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR MONOCLONAL ANTIBODY; POLYVINYL ALCOHOL; SEPHAROSE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGEN SPECIFICITY; BINDING SITE; COMPLEMENT DEPOSITION; COVALENT BOND; EXTRACELLULAR SPACE; EXTRACORPOREAL CIRCULATION; HUMAN; IMMUNOADSORBENT; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LIGAND BINDING; MYASTHENIA GRAVIS; NEUROMUSCULAR TRANSMISSION; PASSIVE IMMUNIZATION; PHAGE DISPLAY; PICHIA PASTORIS; PLASMAPHERESIS; POSTSYNAPTIC MEMBRANE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROCESSING; RECEPTOR BINDING; REVIEW; THYMECTOMY;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; AUTOANTIGENS; BLOOD COMPONENT REMOVAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSORBENTS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; MYASTHENIA GRAVIS; PLASMA EXCHANGE; RECEPTORS, NICOTINIC; THERAPIES, INVESTIGATIONAL; THYMECTOMY;

EID: 77955896409     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916930903518099     Document Type: Review

References (68)

1. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002;2:797-804.
2. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7(3):365-368.
3. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054-1059.
4. Lang B, Newsom-Davis J, Prior C, Wray D. Antibodies to motor nerve terminals: An electrophysiological study of a human myasthenic syndrome transferred to mouse. J Physiol 1983;344:335-345.
5. Mossman S, Vincent A, Newsom-Davis J. Passive transfer of myasthenia gravis by immunoglobulins: Lack of correlation between AChR with antibody bound, acetylcholine receptor loss and transmission defect. J Neurol Sci 1988;84:15-28.
6. Engel AG, Sahashi K, Fumagalli G. The immunopathology of acquired myasthenia gravis. Ann N Y Acad Sci 1981;377: 158-174.
7. Pinching AJ, Peters DK, Newsom-Davis J. Remission of myasthenia gravis following plasma-exchange. Lancet 1976;2: 1373-1376.
8. Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science 1973;180:871-872.
9. Jha S, Xu K, Maruta T, Oshima M, Mosier DR, Atassi MZ, Hoch W. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat musclespecific kinase (MuSK). J Neuroimmunol 2006;175(1-2): 107-117.
10. Tzartos S, Hochschwender S, Vasquez P, Lindstrom J. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J Neuroimmunol 1987;15:185-194.
11. Tzartos SJ, Bitzopoulou K, Gavra I, Kordas G, Jacobson L, Kostelidou K, Lagoumintzis G, Lazos O, Poulas K, Sideris S, Sotiriadis A, Trakas N, Zisimopoulou P. Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera. Ann N Y Acad Sci 2008;1132:291-299.
12. Kaminski HJ. Treatment of myasthenia gravis. In: Current Clinical Neurology: Myasthenia gravis and Related Disorders. New York: Humana Press; 2003. p 197-221.
13. Fostieri E, Kostelidou K, Poulas K, Tzartos SJ. Recent advances in the understanding and therapy of myasthenia gravis. Future Neurol 2006;1:799-801.
14. Chiu HC, Chen WH, Yeh JH. The six year experience of plasmapheresis in patients with myasthenia gravis. Ther Apher 2000;4:291-295.
15. Yeh JH, Chiu HC. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis. J Neurol 2000; 247(7):510-513.
16. Gajdos P, Outin HD, Morel E, Raphael JC, Goulon M. High-dose intravenous gamma globulin for myasthenia gravis: Analternative to plasmaexchange. Ann N Y Acad Sci 1987; 505:842-844.
17. Ferrero B, Durelli L, Cavallo R, Dutto A, Aimo G, Pecchio F, Bergamasco B. Therapies for exacerbation of myasthenia gravis. The mechanism of action of intravenous high-dose immunoglobulin G. Ann N Y Acad Sci 1993;681:563-566.
18. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004;291:2367-2375.
19. Brannagan TH, III, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996;47(3):674-677.
20. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immuneglobulin. N Engl J Med 2001;345:747-755.
21. Dalakas MC. Immunotherapies in the treatment of neuromuscular disorders. Neuromuscular disorders in clinical practice. Boston: Butterworth Heinemann; 2002. p 364-383.
22. Verschuuren JJ, Graus YM, Tzartos JS, van Breda Vriesman PJ, De Baets MH. Paratope- and framework-related cross-reactive idiotopes on anti-acetylcholine receptor antibodies. J Immunol 1991;146(3):941-948.
23. Souroujon MC, Pachner AR, Fuchs S. The treatment of passively transferred experimental myasthenia with antiidiotypic antibodies. Neurology 1986;36(5):622-625.
24. Wang ZY, Qiao J, Link H. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J Neuroimmunol 1993;44(2): 209-214. (Pubitemid 23161401)
25. Im SH, Barchan D, Maiti PK, Raveh L, Souroujon MC, Fuchs S. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB J 2001;15(12):2140-2148.
26. Wu JM, Wu B, Miagkov A, Adams RN, Drachman DB. Specific immunotherapy of experimental myasthenia gravis in vitro: The "guided missile" strategy. Cell Immunol 2001; 208(2):137-147.
27. Psaridi-Linardaki L, Trakas N, Mamalaki A, Tzartos SJ. Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen-specific therapeutic strategy. J Neuroimmunol 2005;159:183-191.
28. Kostelidou K, Trakas N, Tzartos SJ. Extracellular domains of the beta, gamma and epsilon subunits of the human acetylcholine receptor as immunoadsorbents for myasthenic autoantibodies: A combination of immunoadsorbents results in increased efficiency. J Neuroimmunol 2007;190(1-2): 44-52.
29. Zisimopoulou P, Lagoumintzis G, Poulas K, Tzartos S. Antigen-specific apheresis of human anti-acetylcholine receptor autoantibodies from myasthenia gravis patients' sera using Escherichia coli-expressed receptor domains. J Neuroimmunol 2008;200(1-2):133-141.
30. Fostieri E, Tzartos SJ, Berrih-Aknin S, Beeson D,Mamalaki A. Isolation of potent human Fab fragments against a novel highly immunogenic region on human muscle acetylcholine receptor which protect the receptor frommyasthenic autoantibodies. Eur J Immunol 2005;35(2):632-643.
31. Mamalaki A, Trakas N, Tzartos SJ. Bacterial expression of a single-chain Fv fragment which efficiently protects the acetylcholine receptor against antigenic modulation caused by myasthenic antibodies. Eur J Immunol 1993;23(8): 1839-1845.
32. Papanastasiou D, Mamalaki A, Eliopoulos E, Poulas K, Liolitsas C, Tzartos SJ. Construction and characterization of a humanized single chain Fv antibody fragment against the main immunogenic region of the acetylcholine receptor. J Neuroimmunol 1999;94(1-2):182-195.
33. Tsantili P, Tzartos SJ, Mamalaki A. High affinity single-chain Fv antibody fragments protecting the human nicotinic acetylcholine receptor. J Neuroimmunol 1999;94(1-2): 15-27.
34. Sophianos D, Tzartos SJ. Fab fragments of monoclonal antibodies protect the human acetylcholine receptor against antigenic modulation caused by myasthenic sera. J Autoimmun 1989;2(6):777-789.
35. PapanastasiouD, Poulas K, Kokla A, Tzartos SJ. Prevention of passively transferred experimental autoimmune myasthenia gravis by Fab fragments of monoclonal antibodies directed against the main immunogenic region of the acetylcholine receptor. J Neuroimmunol 2000;104(2):124-132.
36. Protopapadakis E, Kokla A, Tzartos SJ, Mamalaki A. Isolation and characterization of human anti-acetylcholine receptor monoclonal antibodies from transgenic mice expressing human immunoglobulin loci. Eur J Immunol 2005;35(6): 1960-1968.
37. Meng F, Stassen MH, Schillberg S, Fischer R, De Baets MH. Construction and characterization of a single-chain antibody fragment derived from thymus of a patient with myasthenia gravis. Autoimmunity 2002;35:125-133.
38. Graus YF, De Baets MH, van Breda Vriesman PJ, Burton DR. Anti-acetylcholine receptor Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies. Immunol Lett 1997;57(1-3):59-62.
39. Van Der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Mart́nez-Mart́nez P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA, De Baets MH, van De Winkel JG, Aalberse RC, Parren PW. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007;317(5844):1554-1557.
40. Karlin A. Emerging structure of the nicotinic acetylcholine receptors. Nat Rev Neurosci 2002;3:102-114.
41. Psaridi-Linardaki L, Mamalaki A, Remoundos M, Tzartos SJ. Expression of soluble ligand and antibody-binding extracellular domain of human muscle acetylcholine receptor alpha subunit in yeast Pichia pastoris. Role of glycosylation in alphabungarotoxin binding. J Biol Chem 2002;277:26980-26986.
42. Kostelidou K, Trakas N, Zouridakis M, Bitzopoulou K, Sotiriadis A, Gavra I, Tzartos SJ. Expression and characterization of soluble forms of the extracellular domains of the beta, gamma and epsilon subunits of the human muscle acetylcholine receptor. FEBS J 2006;273:3557-3568.
43. Bitzopoulou K, Kostelidou K, Poulas K, Tzartos SJ. Mutant forms of the extracellular domain of the human acetylcholine receptor-subunit with improved solubility and enhanced antigenicity. The importance of the Cys-loop. Biochim Biophys Acta 2008;1784(9):1226-1233.
44. Zouridakis M, Kostelidou K, Sotiriadis A, Stergiou C, Eliopoulos E, Poulas K, Tzartos SJ. Circular dichroism studies of extracellular domains of human nicotinic acetylcholine receptors provide an insight into their structure. Int J Biol Macromol 2007;41:423-429.
45. Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, Van Der Oost J, Smit AB, Sixma TK. Crystal structure of an AChbinding protein reveals the ligand binding domain of nicotinic receptors. Nature 2001;411:269-276.
46. Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J Mol Biol 2005;346:967-989.
47. Yamazaki Z, Fujimori Y, Takahama T, Inoue N, Wada T, Kazama M, Morioka M, Abe T, Yamawaki N, Inagaki K. Efficiency and biocompatibility of a new immunosorbent. Trans Am Soc Artif Intern Organs 1982;28:318-323.
48. Matic G, Winkler RE, Tiess M, Ramlow W. Selective apheresis- time for a change. Int J Artif Organs 2001;24:4-7.
49. Ptak J. Changes of plasma proteins after immunoadsorption using Ig-Adsopak columns in patients with myasthenia gravis. Transfus Apher Sci 2004;30(2):125-129.
50. Takamori M, Maruta T. Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor. Therap Apher 2001;5: 340-350.
51. Guo CY, Li ZY, Xu MQ, Yuan JM. Preparation of an immunoadsorbent coupled with a recombinant antigen to remove anti-acetylcholine receptor antibodies in abnormal serum. J Immunol Meth 2005;303:142-147.
52. Lindstrom J, Campbell M, Nave B. Specificities of antibodies to acetylcholine receptors. Muscle Nerve 1978;1:140-145.
53. Loutrari H, Tzartos SJ, Claudio T. Use of Torpedo-mouse hybrid acetylcholine receptors reveals immunodominance of the alpha subunit in myasthenia gravis antisera. Eur J Immunol 1992;22:2949-2956.
54. Psaridi-Linardaki L, Mamalaki A, Tzartos SJ. Future therapeutic strategies in autoimmune myasthenia gravis. Ann N Y Acad Sci 2003;998:539-548.
55. Burnouf T, Eber M, Kientz D, Cazenave JP, Burkhardt T. Assessment of complement activation during membranebased plasmapheresis procedures. J Clin Apher 2004;19(3): 142-147.
56. Kalamida D, Poulas K, Avramopoulou V, Fostieri E, Lagoumintzis G, Lazaridis K, Sideri A, Zouridakis M, Tzartos SJ. Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity. FEBS J 2007;274(15):3799-3845.
57. Loutrari H, Kokla A, Tzartos SJ. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. Eur J Immunol 1992;22(9): 2449-2452.
58. Vincent A. Aetiological factors in development of myasthenia gravis. Adv Neuroimmunol 1994;4(4):355-371.
59. Tzartos SJ, Sophianos D, Efthimiadis A. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera. J Immunol 1985;134(4): 2343-2349.
60. Tzartos SJ, Barkas T, Cung MT, Mamalaki A, Marraud M, Orlewski P, Papanastasiou D, Sakarellos C, Sakarellos-Daitsiotis M, Tsantili P, Tsikaris V. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev 1998;163: 89-120.
61. Tzartos SJ, Lindstrom JM. Monoclonal antibodies used to probe acetylcholine receptor structure: Localization of the main immunogenic region and detection of similarities between subunits. Proc Natl Acad Sci USA 1980;77(2):755-759.
62. Tzartos SJ, Seybold ME, Lindstrom JM. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc Natl Acad Sci 1982;79(1):188-192.
63. Heidenreich F, Vincent A, Willcox N, Newsom-Davis J. Anti-acetylcholine receptor antibody specificities in serum and in thymic cell culture supernatants from myasthenia gravis patients. Neurology 1988;38(11):1784-1788.
64. Lennon VA, Griesmann GE. Evidence against acetylcholine receptor having a main immunogenic region as target for autoantibodies in myasthenia gravis. Neurology 1989;39(8): 1069-1076.
65. Trakas N, Tzartos SJ. Conjugation of acetylcholine receptorprotecting Fab fragments with polyethylene glycol results in a prolonged half-life in the circulation and reduced immunogenicity. J Neuroimmunol 2001;120(1-2):42-49.
66. Farrar J, Portolano S, Willcox N, Vincent A, Jacobson L, Newsom-Davis J, Rapoport B, McLachlan SM. Diverse Fab specific for acetylcholine receptor epitopes from a myasthenia gravis thymus combinatorial library. Int Immunol 1997;9(9): 1311-1318.
67. Schuurman J, Van Ree R, Perdok GJ, Van Doorn HR, Tan KY, Aalberse RC. Normal human immunoglobulin G4 is bispecific: It has two different antigen-combining sites. Immunology 1999;97(4):693-698.
68. Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology 2002;105(1):9-19.